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2014, accepted Feive years after convening the expert panel, the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to
Reduce Atherosclerotic Cardiovascular Risk in Adults was released. The American College of Cardiology and
American Heart Association issued the guideline on the basis of a systematic review of cholesterol treatment trials
performed by the National Heart, Lung, and Blood Institute. This report critically appraises the guideline and provides
our view of what was done well and what could be done better. In particular, we propose that the guideline succeeds
in prioritizing statin therapy, expanding the focus to atherosclerotic cardiovascular disease (including stroke), and
emphasizing absolute cardiovascular risk to determine eligibility for statin therapy. We contend that the guideline
could be enhanced by reﬁning the use of lipid goals rather than removing them, enhancing guidance on evaluation
of cholesterol, and broadening the concept of age underpinning risk-based decision making to include vascular and
physiological age. We further suggest that the next guideline panel could comprehensively review current best
evidence, build on existing guidelines, and cultivate broader national and international consensus. Overall, we aim to
continue discussions about the important contributions and shortfalls of the guideline and create momentum for
effective implementation and timely updates. (J Am Coll Cardiol 2014;63:2674–8) ª 2014 by the American
College of Cardiology FoundationFive years after it was commissioned, the document previ-
ously known as “ATP IV” was issued on November 12, 2013,
under a revised name, “2013 ACC/AHA Guideline on the
Treatment of Blood Cholesterol to Reduce Atherosclerotic
Cardiovascular Risk in Adults” (henceforth abbreviated as
“CTG” for “Cholesterol Treatment Guideline”) (1). The
American College of Cardiology and American Heart Asso-
ciation (ACC/AHA) issued the CTG on the basis of a sys-
tematic review of cholesterol treatment trials. This report
critically appraises the CTG and provides our view of what was
done well and what could be done better in future iterations.
What Was Done Well
Prioritizing statin therapy. The CTG succeeds in priori-
tizing statin therapy, which is in line with recommendations
from our group (2) and others (3). Over the decade sinceopkins Ciccarone Center for the Prevention of Heart Disease,
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bruary 25, 2014.the original publication of the Adult Treatment Panel
(ATP) III guideline, the Cholesterol Treatment Trialists’
Collaboration has further expanded the extraordinary wealth
of information on statin therapy (4,5). This class of medi-
cations is 1 of the best validated to reduce the morbidity
and mortality from atherosclerotic cardiovascular disease
(ASCVD) and has an excellent safety proﬁle (1,2,4). More-
over, generic options for moderate- and high-intensity statin
formulations are now available. We anticipate that priori-
tizing statins will lead to much less use of nonstatin therapy
in patients not yet on maximally tolerated statin therapy.
Expanding the focus to ASCVD. Cerebrovascular disease
and coronary heart disease (CHD) share risk factors and the
underlying disease process of atherosclerosis. Lipid-lowering
interventions reduce clinical events related to ASCVD, not
only CHD. Therefore, addressing the broader disease
construct is justiﬁed and more efﬁcient.
There are complexities to this expanded paradigm, not
limited to the fact that 1 of multiple underlying patho-
physiological mechanisms can cause a stroke, and the
distinction can be challenging to adjudicate. Although we
must carefully scrutinize and understand how to manage
such complexities, on balance, expanding the framework
from CHD to ASCVD is an important and welcome
change (6).
Emphasizing absolute cardiovascular risk. The CTG
emphasizes absolute risk in the allocation of statin therapy.
The CTG recommends moderate- to high-intensity statin
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2675therapy in groups with high absolute risk, including patients
with clinical ASCVD, those 40 to 75 years of age with
diabetes mellitus, and those with low-density lipoprotein
cholesterol (LDL-C) levels 190 mg/dl. The CTG prior-
itizes these 3 groups on the basis of prevailing evidence from
randomized controlled trials.
For those not in one of these groups, if the patient has an
LDL-C level of 70 to 189 mg/dl and is 40 to 75 years of age,
then the CTG advises calculation of 10-year risk of ASCVD
on the basis of traditional risk factors using new sex- and
race-stratiﬁed pooled cohort equations developed by the
ACC/AHA Risk Assessment Working Group (7). Concern
about overestimation of risk by these equations is being
debated (8,9), and further validation studies are necessary.
Nevertheless, we appreciate the intention to address absolute
risk in primary prevention. In the CTG, the risk calculator
does not mandate drug prescription but rather serves as a
starting point for a discussion about risk between the patient
and the clinician. This discussion may lead to additional
testing to reﬁne the estimate of absolute risk. The CTG
identiﬁes the intermediate-risk group as people with a 5% to
7.5% 10-year risk of ASCVD and recommends a discussion
about risk in people with 7.5% risk.What Could Be Done Better
Reﬁne the use of lipid goals rather than remove
them. There are potential downsides to lipid goals. They
could lead to overuse of nonstatin agents and combination
regimens instead of maximizing statin therapy. This could
increase the propensity for adverse effects, which could be
problematic speciﬁcally in primary prevention patients with
less certain absolute ASCVD risk and, therefore, less certain
beneﬁts. Moreover, lipid goals could conceivably result in
withholding of efﬁcacious treatment in a person with an
LDL-C level <100 mg/dl. Prior guidelines may not have
recommended intensive statin therapy, or a statin at all, in
higher-risk patients with low or average off-treatment levels
of LDL-C (100 to 130 mg/dl), yet this group has a similar
proportional risk reduction from lowering of LDL-C levels
(4). Therefore, applying a lipid goal at baseline could lead
to underuse of statins in higher-risk patients.
We could address these issues without abandoning lipid
goals. To do so, we could refocus the use of lipid goals as an
option to guide residual risk discussions on follow-up among
those with a clearly established risk of ASCVD while
making it explicitly clear that maximizing the statin dose is
the ﬁrst priority. Even in secondary prevention trial pop-
ulations carefully selected to adhere to high-intensity statin
therapy, many patients did not attain optimal levels of
atherogenic cholesterol. In statin-treated patients, LDL-C,
non–high-density lipoprotein cholesterol (non–HDL-C),
and apolipoprotein B are markers of residual risk (10).
Considering LDL-C and non–HDL-C on follow-up in
relation to explicit goals, as was done in ATP III, could alert
the patient and provider that levels are still suboptimal. Thisdoes not need to trigger auto-
matic addition of drug therapy.
Rather, it could prompt a dis-
cussion of residual risk and op-
tions for further intensiﬁcation of
lifestyle improvements and add-
on drug therapy, particularly in
the setting of an elevated tri-
glyceride level and a low HDL-C
level. Because the anticipated net
beneﬁts of further lipid lowering
are clearest in those with the
most clearly established risk, we
believe that lipid goals are best
justiﬁed in high-risk secondary
prevention.
It is true that there has not been
a deﬁnitive randomized clinical
trial of the addition of a second
lipid-lowering agent in secondary
prevention patients with residu-
ally elevated atherogenic choles-
terol levels. There are many clinical situations, including
in the management of hypertension, in which there are no
randomized trials of ASCVD outcomes with the addition
of drug A to drug B or the addition of drug C to drugs A
and B. However, we could learn from landmark strategy
trials such as the COURAGE (Clinical Outcomes Uti-
lizing Revascularization and Aggressive Drug Evaluation)
trial, in which statins and nonstatins were titrated to an
LDL-C goal of 60 to 85 mg/dl. The central test of the
trial was optimal medical therapy with or without percu-
taneous coronary intervention, and it forms part of the
foundation for management of patients with stable CHD.
A COURAGE-like strategy to medical management in-
cludes an LDL-C goal.
As previously reviewed (11,12), complementary lines of
evidence support the low LDL-C goal used in the COURAGE
trial (or similar goals such as<80 or<70 mg/dl). First, LDL-C
levels in this range appear to be evolutionarily or biologically
normal. Second, those with genetically determined low
LDL-C levels are strongly protected from ASCVD. Third,
trials and observational studies have consistently shown a
log-linear association of lower LDL-C level with lower risk
of ASCVD. Fourth, populations treated to low LDL-C
levels in trials were more likely to have stabilization or
regression of atherosclerosis. Fifth, the Cholesterol Treat-
ment Trialists’ Collaboration has shown that the beneﬁt of
statin therapy is tied not only to absolute ASCVD risk but
also to the absolute lowering of LDL-C levels, with each
39-mg/dl (1-mmol/l) reduction in LDL-C level decreas-
ing the incidence of ASCVD by approximately one-ﬁfth.
Finally, subgroups of patients attaining the lowest LDL-C
levels in these trials had the best outcomes without any
signiﬁcant increases in major adverse effects. Therefore, like
COURAGE, ATP III, and guidelines in Europe and
Martin et al. JACC Vol. 63, No. 24, 2014
Analysis of the 2013 Cholesterol Guideline June 24, 2014:2674–8
2676Canada, we could use this information to manage residually
elevated LDL-C levels.
Because LDL-C will not capture triglyceride-rich
remnant lipoproteins, we could also consider non–HDL-C
or apolipoprotein B. A previous meta-analysis of statin and
nonstatin lipid-lowering drugs used as monotherapy found a
w1:1 percent lowering between non–HDL-C level and risk
of CHD (13). Pre-speciﬁed subgroup analyses of trial par-
ticipants with high triglyceride and low HDL-C levels
(markers for remnants) are informative on the potential
beneﬁt of adding a ﬁbrate (14) or niacin (14,15) to statin
therapy. These studies have shown a consistent trend for
beneﬁt.
Therefore, “treating risk” and “treating lipids” are not
mutually exclusive and are actually complementary. Absolute
risk places the lipids in context and can guide discussions
weighing potential beneﬁts and harms. However, lipid goals
provide a marker for adequacy of lipid lowering. They not
only help ensure adherence to lifestyle improvements and
statin therapy but also help guide therapy in high-risk
patients in whom these treatments are exhausted.
Enhance guidance on evaluation of cholesterol. The
CTG does not include “evaluation” in its title, as it was in
ATP III. However, new information has become available
on the evaluation of cholesterol since ATP III. Although the
risk assessment guideline examines this information to some
extent, evaluation of cholesterol is not purely an issue of risk
assessment.
For example, at baseline, the CTG recommends treat-
ment if the LDL-C level is 70 mg/dl but not if it
is <70 mg/dl. Therefore, accurate measurement in the in-
dividual patient is critical to management. Expanding prior
evidence, we have shown that of patients who have a
Friedewald-estimated LDL-C level <70 mg/dl, 23% have a
directly measured LDL-C level 70 mg/dl (39% if the
triglyceride level is 150 to 199 mg/dl and 59% if the
triglyceride level is 200 to 399 mg/dl) (16). If externally
validated, a novel method for estimation of LDL-C levels
could resolve much of the underestimation of LDL-C levels
by accounting for variation in the relationship of triglycerides
to very-low-density lipoprotein cholesterol (17).
The next guideline could translate new knowledge on
cholesterol evaluation. It could take a leadership role in guiding
clinicians on not only LDL-C but also non–HDL-C, apoli-
poprotein B, and LDL particle concentration. Along with the
science, there are historical, ﬁnancial, and logistical consider-
ations, and an expert panel is well suited to weigh these factors.
Broaden the concept of age. The CTG emphasizes
chronological age in treatment decisions. For example, the
CTG explicitly recommends statin therapy only in patients
who are 40 to 75 years of age. This same age range also
determines who undergoes 10-year ASCVD risk calculation
to guide treatment decisions. Age dominates the risk
calculator, with the 7.5% risk threshold exceeded by nearly
all men in their mid to late 60s and nearly all women in their
70s despite an optimal risk factor proﬁle.However, people age differently. We submit that a broader
construct of age may enhance risk discussions and treatment
decisions. “Heart age” and “vascular age” could help patients
better understand how their risk compares with their chro-
nological age. Moreover, the concepts of “health age” or
“physiological age” could be used to assess our patients’
noncardiovascular comorbidities or competing risks, which
could affect the net beneﬁts from intervention. If the patient
is free of competing risks, then we would suggest that the
CTG could be less cautious in those older than 75 years of
age. The meta-analysis by the Cholesterol Treatment Tria-
lists’ Collaboration included 1,872 events in subjects older
than 75 years of age, and there was no evidence of hetero-
geneity of treatment effect by age (4). A meta-analysis
focused on elderly patients without ASCVD at baseline, in-
volving 24,674 subjects with a mean age of 73.0  2.9 years
and 3.5  1.5 years of follow-up, found a signiﬁcant
reduction in ASCVD outcomes with statin therapy (18).
We would also like to prevent signiﬁcant accumulation of
atherosclerosis earlier in life. A risk score dominated by
chronological age favors late treatment. Once atherosclerosis
progresses to an advanced stage, there may be an associated
degree of unmodiﬁable risk. Although speculative, pre-
venting signiﬁcant progression of atherosclerosis in the ﬁrst
place may help avoid at least part of this residual risk. It is
striking that the relative risk reduction associated with a
genetically low LDL-C level is larger than that with later-
stage drug therapy (19).
We submit the following for debate: if you are stuck on a
deserted island, have signiﬁcant subclinical atherosclerosis or
heterozygous familial hyperlipidemia with an LDL-C level
of 189 mg/dl, and have only enough statin to take for 20
years, would you take it from 30 to 50 years of age or 50 to
70 years of age?
Comprehensively review current best evidence, build
on existing guidelines, and reﬁne the CTG during
implementation. Evidence-based medicine is “the con-
scientious, explicit, and judicious use of current best evidence
in making decisions about the care of individual patients”
(20). Aimed at supporting evidence-based medicine, the
CTG conducted a systematic search of randomized
controlled trials through December 2009, and was also
allowed to consider trials through July 2013. The phrase “no
evidence” could be a dangerous claim (21), especially when
all current best evidence has not been considered.
A search on PubMed for “cholesterol” on the day the
CTG was released yielded 219,290 published scientiﬁc
reports. In answering “Critical Question 1” about lipid goals,
the CTG screened 2,224 titles and abstracts, that is, w1%
of the published literature.
To construct a comprehensive guideline, the writing group
did not necessarily need to re-review >200,000 published
scientiﬁc reports. The ATP III critically appraised and syn-
thesized the relevant literature through 2004 (22). In addi-
tion, specialty societies such as the National Lipid Association
(NLA) (23) and the American Association of Clinical
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mendations for the management of cholesterol disorders.
The NLA and the AACE each provided input to the
National Heart, Lung, and Blood Institute and ACC/AHA
during the development of the CTG but ultimately did not
endorse the document. The reasons why the NLA and the
AACE each did not endorse the CTG were explained in
public statements (25,26). Each group cited the highly
restrictive consideration of evidence, removal of lipid targets,
too little guidance on nonstatin options, and insufﬁcient
consideration of special populations of patients.
Outside of the United States, while the United Kingdom
just released a provisional guideline for stakeholder
comment (27), experts in Europe (28) and Canada (29,30)
have already completed updated guidelines. The Interna-
tional Atherosclerosis Society has also released a position
paper on the management of dyslipidemia (31). These in-
ternational efforts address many of the concerns noted by
the NLA and AACE. In moving forward, we propose
building on these prior efforts. Ideally, the ACC/AHA
could collaborate with professional societies around the
globe to build broader consensus and produce an interna-
tional consensus guideline on cholesterol treatment.
It is easy to imagine the potential beneﬁts to guideline
implementation from pooling resources and broadening
consensus. The critical rollout phase of the CTG could
leverage the inﬂuence of professional societies and engage the
expertise of transdisciplinary teams inclusive of implementa-
tion scientists to help overcome barriers to guideline adher-
ence at the bedside. For example, guideline documents such as
the CTG can be long, tedious, and very repetitive. Although
an important scholarly exercise, this form of information is far
from user-friendly. Instead, implementation scientists
recommend a prioritized checklist of unambiguous behaviors
organized in time and space, citing the level of evidence (32).
A checklist could be printed and posted in the clinic, made
available online, or included in a smartphone app.
Implementation scientists have identiﬁed a number of
other barriers to guideline adherence, including lack of
awareness or ability, clinical inertia, disagreement with rec-
ommendations, or ambiguity of recommendations (32).
Regarding the latter, although ﬁgures illustrating the ﬂow of
key guideline recommendations are valuable, their inter-
pretation may be ambiguous when related ﬁgures are
disjointed or when critical information is buried in footnotes
or text. The implementation phase of the CTG could
beneﬁt from observing clinicians trying to use the guideline
and striving to understand and respond to stumbling points.
As such, we hope that the initial release of the CTG will
function as a living document open to reﬁnement as a result
of feedback provided during its implementation.
Conclusions
We have highlighted key aspects of what was done well by
the CTG and what could be done better. Because theguideline was not released for public comment before its
publication, we hope that a careful discussion about its
content will continue, involving patients, health pro-
fessionals, scientists, health systems, and payers. We offer
our initial reactions, aimed at creating momentum for
effective guideline implementation and timely updates that
will support the application of current best evidence to the
care of individual patients.
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